Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772393 | 1.00 | MGLL (0.73) | MGLL | |
| SCHEMBL23773777 | 0.91 | MGLL (0.79) | MGLL | |
| SCHEMBL23772712 | 0.91 | MGLL (0.79) | MGLL | |
| SCHEMBL23773785 | 0.91 | MGLL (0.79) | MGLL | |
| SCHEMBL23752988 | 0.91 | MGLL (0.79) | MGLL | |
| SCHEMBL23752822 | 0.90 | MGLL (0.72) | MGLL | |
| SCHEMBL23772507 | 0.90 | MGLL (0.72) | MGLL | |
| SCHEMBL23772522 | 0.88 | MGLL (0.82) | MGLL | |
| SCHEMBL23752831 | 0.88 | MGLL (0.82) | MGLL | |
| SCHEMBL23752992 | 0.87 | MGLL (0.75) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | claimed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | claimed |
| CN-115066422-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | claimed |
| EP-4384165-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | Janssen Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | claimed |
| CN-118076351-A | Monoacylglycerol lipase modulators for autism spectrum disorders | 詹森药业有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-07 | — | — | US | claimed |
| US-11708359-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-25 | — | — | US | claimed |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-20 | — | — | US | claimed |
| WO-2023019094-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | claimed |
| EP-4103557-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-12-21 | — | — | EP | claimed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | claimed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| CN-115066422-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-11708359-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-25 | — | — | US | disclosed |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-20 | — | — | US | disclosed |
| EP-4103557-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-12-21 | — | — | EP | disclosed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | MGLL 1/4885 |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | MGLL 3/4885 |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | MGLL 3/4885 |
| US-11708359-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, LIPC | MGLL 1/4885 |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | MGLL 3/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | MGLL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.